Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery. Its portfolio includes clonoSEQ, a test used to detect and monitor minimal residual disease in cancer patients, along with immunoSEQ-based offerings for immune profiling and research applications. Adaptive Biotechnologies serves healthcare providers, pharmaceutical partners, researchers, and biotech collaborators across oncology and broader immunology-related markets. Headquartered in Seattle, Washington, the company plays a specialized role in translating immune system data into tools for disease detection and treatment support.